NEW YORK (GenomeWeb News) – Merck said after the close the market yesterday that it has granted Laboratory Corporation of America a non-exclusive license to commercialize a genetic test to help predict patient response to peginterferon alpha-based therapy for hepatitis C virus.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.